Analyst Expectations For Silence Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have evaluated Silence Therapeutics (NASDAQ:SLN), with the majority being bullish. The average 12-month price target has increased by 3.85% to $65.57. Analysts from firms like Chardan Capital and Morgan Stanley have maintained or raised their ratings and price targets, reflecting positive sentiment towards the company.
August 16, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silence Therapeutics (NASDAQ:SLN) has received predominantly bullish ratings from analysts over the past three months. The average 12-month price target has increased by 3.85% to $65.57, with notable positive ratings from Chardan Capital and Morgan Stanley.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment and potential for short-term price appreciation. Notable firms like Chardan Capital and Morgan Stanley have maintained or raised their ratings and price targets, further supporting this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100